DVY
Devyser Diagnost
Stock
Stock
ISIN: SE0016588867
Ticker: DVYSR
SE0016588867
DVYSR
Price
Price
CHART BY
Frequently asked questions
What is Devyser Diagnost's market capitalization?
The market capitalization of Devyser Diagnost is $199.77M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Devyser Diagnost?
Devyser Diagnost's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.354. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Devyser Diagnost's stock?
Currently, 3 analysts cover Devyser Diagnost's stock, with a consensus target price of $16.57. Analyst ratings provide insights into the stock's expected performance.
What is Devyser Diagnost's revenue over the trailing twelve months?
Over the trailing twelve months, Devyser Diagnost reported a revenue of $20.45M.
What is the EBITDA for Devyser Diagnost?
Devyser Diagnost's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$3.85M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Devyser Diagnost?
Devyser Diagnost has a free cash flow of -$6.85M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
What is the free float of Devyser Diagnost's shares?
The free float of Devyser Diagnost is 9.81M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $199.77M
- EPS (TTM)
- -$0.354
- Free Float
- 9.81M
- Revenue (TTM)
- $20.45M
- EBITDA (TTM)
- -$3.85M
- Free Cashflow (TTM)
- -$6.85M
Pricing
- 1D span
- $12.06$12.28
- 52W span
- $8.343$13.59
Analyst Ratings
The price target is $16.57 and the stock is covered by 3 analysts.
Buy
3
Hold
0
Sell
0
Information
Devyser Diagnostics AB engages in the development, manufacture and sale of kits for genetic testing in routine diagnostics. Its products are used for complex DNA testing in the areas of hereditary diseases, oncology and post-transplantation monitoring. The firm's products are also used in treating cancer patients and in follow-up transplant patients. The company was founded by Anders Hedrum, Ulf Axel Klangby and Dan Hauzenberger in 2004 and is headquartered in Hägersten, Sweden.
- Industries
- Medical Specialties
- Sector
- Health Care
Identifier
- ISIN
- SE0016588867
- Primary Ticker
- DVYSR
Knockouts
Finance data from FactSet